Skip to main content

Caprion, Idec Ink CellCarta Collab; Caprion Nabs $4M Equity Investment

NEW YORK, Sept. 17 - Caprion Pharmaceuticals today said it has signed an R&D deal with Idec Pharmaceuticals potentially worth $11 million.

 

The multi-year deal, which landed Caprion a $4 million equity investment, calls for Idec to use Caprion's CellCarta proteomics platform to identify tumor-specific cell-surface antigen targets. The drug discoverer will then use its monoclonal antibody and radioimmunotherapy technologies to develop therapeutics against those targets, the companies said.

 

Beside the $4 million equity investment, Caprion, based in Montreal, stands to earn up to $7 million in tech-access fees over the life of the collaboration. Neither company would specify the intended length of the deal. Certain undisclosed milestones will trigger additional payments to Caprion, the partners said.

 

Click here for more information.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.